Birch Allergy Market

• The Birch Allergy Market size is estimated to grow with a significant CAGR during the forecast period (2023-2032).
• Allergy Therapeutics Plc, Regeneron Pharmaceuticals Inc, Desentum, HAL Allergy Group, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA, Roxall Medizin GmbH, Worg Pharmaceuticals AG, Stallergenes Greer plc, are the leadings companies developing therapies for Birch Allergy Treatment.
• As per a study conducted by “Biedermann et al. (2019) found that birch pollen sensitization ranged from 8% to 16% in the general population of Europe. The population of Japan might have similar rates of sensitization to birch and alder as those in Europe. The dominance of the birch pollen–derived allergens within the homologous group has been demonstrated in inhibition tests of tree-sensitive patients in Europe where a combination of recombinant Bet v 1 and Bet v 2 (a minor birch allergen) inhibited IgE binding to extracts from alder, hornbeam, hazel, and oak by an average of 72%-88%, indicating that together rBet v 1 and rBet v 2 contain 82% of the IgE epitopes present in Fagales pollens.
• The Birch allergy epidemiology covered in the report provides historical as well as forecasted Birch allergy epidemiology segmented as Total Prevalent Cases of Birch allergy, Total Diagnosed Cases of Birch allergy, and Total Treated Cases of Birch allergy in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

Request for unlocking the CAGR of Birch Allergy Market

DelveInsight’s “Birch Allergy Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the birch allergy, historical and forecasted epidemiology as well as the birch allergy market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

The Birch Allergy market report provides current treatment practices, emerging drugs, birch allergy market share of individual therapies, and current and forecasted acute coronary syndrome market size from 2019 to 2032, segmented by the seven major markets. The report also covers current birch allergy treatment practices/algorithms and Birch Allergy unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

Study period: 2019–2032

Birch Allergy Market Treatment Algorithm and Disease Understanding

DelveInsight’s Birch allergy market report gives a thorough understanding of birch allergy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Allergy is a condition that occurs when the body (the immune system) overreacts to something in the environment (triggers). It is caused by allergens, which are usually harmless substances but trigger an allergic reaction in some people. When the symptoms occur in late summer or early fall, some people call it hay fever.

There are different general types of allergy, which include seasonal and perennial. Seasonal allergies, usually due to cyclic airborne plant pollens, are more common and cause problems to individuals at certain times of the year like birch allergy.

Birch allergy Diagnosis

Its diagnosis is made by considering a detailed history that is supported by examination findings (physical examination and, if needed, nasal endoscopy) and, if necessary, testing for allergen-specific IgE.

Birch allergy Treatment

Therapeutic options available to achieve this goal include avoidance measures, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays; leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. Other therapies that may be useful in select patients include decongestants and oral corticosteroids. If the patient’s symptoms persist despite appropriate treatment, referral to an allergist should be considered.

Birch Allergy Epidemiology

The Birch allergy epidemiology section provides insights into the historical and current birch allergy patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the birch allergy report also provides the diagnosed patient pool, their trends and, assumptions undertaken.

Key findings

• As per a study conducted by “Biedermann et al. (2019) found that birch pollen sensitization ranged from 8% to 16% in the general population of Europe. The population of Japan might have similar rates of sensitization to birch and alder as those in Europe. The dominance of the birch pollen–derived allergens within the homologous group has been demonstrated in inhibition tests of tree-sensitive patients in Europe where a combination of recombinant Bet v 1 and Bet v 2 (a minor birch allergen) inhibited IgE binding to extracts from alder, hornbeam, hazel, and oak by an average of 72%-88%, indicating that together rBet v 1 and rBet v 2 contain 82% of the IgE epitopes present in Fagales pollens.
• The Birch allergy epidemiology covered in the report provides historical as well as forecasted Birch allergy epidemiology segmented as Total Prevalent Cases of Birch allergy, Total Diagnosed Cases of Birch allergy, and Total Treated Cases of Birch allergy in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Birch Allergy Epidemiology

The epidemiology segment also provides the Birch allergy epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Birch Allergy Drug Chapters

The drug chapter segment of the Birch allergy report encloses a detailed analysis of a birch allergy marketed drugs and late-stage (Phase III and Phase II) Birch allergy pipeline drugs. It also helps understand the Birch allergy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Birch Allergy Drugs

The report details the emerging birch allergy therapies under the late and mid-stage of development for Birch allergy treatment.

REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch allergy can trigger reactions such as allergic rhinitis and asthma. The Bet v1–specific mAbs (REGN5713, REGN5714, and REGN5715) were generated using Regeneron’s VelocImmune platform. Preclinical studies demonstrated that the three mAbs bind independently and non-competitively to Bet v 1 and that all three together provided maximal inhibition of Bet v 1 binding to human polyclonal IgE and potently blocked basophil activation ex vivo and mast cell degranulation in vivo.

Note: detailed emerging therapies assessment will be provided in the full report of moderate psoriasis

Birch Allergy Market Outlook

The birch allergy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted birch allergy market trends by analyzing the impact of current therapies on the market, Birch Allergy unmet needs, and demand for better technology.

This segment gives a thorough detail of the birch allergy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key players, such as, Regeneron Pharmaceuticals and ALK-Abelló A/S are involved in developing drugs for Allergic rhinitis.

According to DelveInsight, the birch allergy market in the 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Birch allergy market in the 7MM.

The United States: Birch Allergy Market Outlook

This section provides the total Birch allergy market size and market size by therapies in the United States.

EU4 and the UK: Birch Allergy Market Outlook

The total Birch allergy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Birch Allergy Market Outlook

The total Birch allergy market size and market size by therapies in Japan are also mentioned.

Birch Allergy Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the birch allergy market or expected to get launched in the market during the study period 2019–2032. The analysis covers birch allergy market uptake by drugs, patient uptake by therapies, and sales of each drug.

This will help in understanding the birch allergy drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Birch Allergy Pipeline Development Activities

The Birch Allergy report provides insights into Birch Allergy Clinical Trials within Phase II, and Phase III stages. It also analyses birch allergy’s key players involved in developing targeted therapeutics.

Birch allergy Clinical Trial Development Activities

The birch allergy clinical trials report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information on Birch allergy emerging therapies.

Birch Allergy Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the acute coronary syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Birch allergy market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Birch Allergy unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Birch allergy market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of Birch Allergy Market Report

• Descriptive overview of the Birch allergy, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Birch allergy epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for the Birch allergy, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Birch allergy market; historical and forecasted covering drug outreach in the 7MM
• Trends shaping and driving the global Birch allergy market

Birch Allergy Market Report Highlights

• In the coming years, the Birch allergy market is set to change due to the launch of upcoming therapies; which would expand the size of the market
• The companies and academics are working to assess challenges and seek opportunities that could influence acute coronary syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing Birch allergy therapies. The launch of emerging therapies will significantly impact the Birch allergy market
• A better understanding of Birch allergy pathogenesis will also contribute to the development of novel therapeutics for the Birch allergy
• Our in-depth analysis of the Birch allergy pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Birch Allergy Report Insights

• Patient-Based Birch Allergy Market Forecasting
• Birch allergy Therapeutic approaches
• Birch allergy pipeline analysis
• Birch allergy market size and trends
• Birch allergy market opportunities
• Impact of upcoming therapies

Birch Allergy Report Key Strengths

• 10 years forecast
• The 7MM coverage
• Birch allergy epidemiology segmentation
• Key cross competition
• KOL views
• Birch allergy drugs uptake

Birch Allergy Report Assessment

• Current Birch allergy treatment practices
• Birch Allergy Unmet needs
• Birch allergy Pipeline product profiles
• Birch Allergy Market attractiveness
• Birch allergy Market Drivers
• Birch allergy Market Barriers

Key Questions Answered In The Birch Allergy Market Report

Birch Allergy Market Insights:

• What would be the birch allergy market growth till 2032, and what will be the resultant market size in 2032?
• What was the birch allergy drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the birch allergy total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across the 7MM, and which country will have the largest Birch allergy market size during the forecast period (2019–2032)
• How would the unmet needs affect the birch allergy market dynamics and subsequent analysis of the associated trends?

Birch Allergy Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Birch allergy?
• What is the historical and forecasted acute coronary syndrome patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for the seven major markets covering the United States, EU4 (Germany, Spain, France, Italy) and the UK, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for acute coronary syndrome in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to acute coronary syndrome therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for birch allergy and its status, along with the challenges faced?

Reasons to Buy Birch Allergy Market Report

• The patient-based birch allergy market forecasting report will help in developing business strategies by understanding trends shaping and driving the Birch allergy market
• Organize sales and marketing efforts by identifying the best opportunities for acute coronary syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors